The Pfizer Inc.-backed startup SpringWorks Therapeutics reinforces the fact that even the largest pharmaceutical companies in the world don't have enough resources to develop every potentially good idea curated by their scientists.
That's why Pfizer spun out four compounds into the newly launched, privately-held SpringWorks, which raised $103m in Series A venture capital with the big pharma as one of its investors....
SpringWorks Founder and President and six-year Pfizer veteran Lara Sullivan said in an interview that in big pharma companies, "you find yourself with this steady-state problem of too much good...
